for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adial Pharmaceuticals Inc

ADIL.OQ

Latest Trade

1.92USD

Change

-0.14(-6.80%)

Volume

63,089

Today's Range

1.92

 - 

2.10

52 Week Range

1.00

 - 

4.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.06
Open
2.07
Volume
63,089
3M AVG Volume
13.88
Today's High
2.10
Today's Low
1.92
52 Week High
4.00
52 Week Low
1.00
Shares Out (MIL)
14.39
Market Cap (MIL)
27.63
Forward P/E
-2.16
Dividend (Yield %)
--

Latest Developments

More

Adial Pharmaceuticals Says U.S. FDA Reactivated Adial'S U.S. IND Application, Lifted Clinical Hold From AD04

Adial Pharmaceuticals And Biolab Sciences Enter Into Distribution Agreement For Covid-19 Antibody Tests

Adial Pharmaceuticals Inc says On May 26, Reached Understanding On Terms To Purchase Covid-19 IgG / IgM Rapid Test Kits

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of medications for the treatment of addictions and related disorders. Its lead investigational drug product is AD04. AD04 is being developed for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist. AD04 is being designed to be used for the treatment of other addictive disorders, such as opioid use disorder, obesity, smoking, and other drug addictions.

Industry

Biotechnology & Drugs

Contact Info

1180 SEMINOLE TRAIL, SUITE 495

CHARLOTTESVILLE, VA

22901

United States

+1.434.4229800

https://www.adialpharma.com/

Executive Leadership

William B. Stilley

President, Chief Executive Officer, Director

Kevin Schuyler

Vice Chairman, Lead Independent Director

Joseph Truluck

Chief Financial Officer, Chief Operating Officer, Treasurer, Secretary

Bankole A. Johnson

Chief Medical Officer

J. Kermit Anderson

Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2020(E)

0.0K
EPS (USD)

2018

-1.710

2020(E)

-0.890
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.85
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-119.91
Return on Equity (TTM)
-107.23

Latest News

Latest News

BRIEF-Adial Pharmaceuticals Announces Approval To Commence Landmark Onward!" Pivotal Phase 3 Trial In Poland

* ADIAL PHARMACEUTICALS ANNOUNCES APPROVAL TO COMMENCE LANDMARK ONWARD!" PIVOTAL PHASE 3 TRIAL IN POLAND

BRIEF-Adial Pharmaceuticals Files Prospectus Supplement Related To Offering Of 2.8 Mln Common Shares

* ADIAL PHARMACEUTICALS FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING OF 2.8 MILLION COMMON SHARES - SEC FILING Source: https://bit.ly/2BRIRoN Further company coverage:

BRIEF-Adial Pharmaceuticals And Biolab Sciences Enter Into Distribution Agreement For Covid-19 Antibody Tests

* ADIAL PHARMACEUTICALS AND BIOLAB SCIENCES ENTER INTO DISTRIBUTION AGREEMENT FOR COVID-19 ANTIBODY TESTS

BRIEF-Adial Pharmaceuticals Inc says On May 26, Reached Understanding On Terms To Purchase Covid-19 IgG / IgM Rapid Test Kits

* ADIAL PHARMACEUTICALS INC - ON MAY 26, REACHED UNDERSTANDING ON TERMS TO PURCHASE COVID-19 IGG / IGM RAPID TEST KITS

BRIEF-Adial Pharmaceuticals Inc Files For Mixed Shelf Of Up To $50 Million – SEC Filing

* ADIAL PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $50 MILLION – SEC FILING Source text for Eikon: https://bit.ly/2VsiyNq Further company coverage:

BRIEF-Adial Pharmaceuticals Provides Update On Onward9 Phase 3 Pivotal Trial

* ADIAL PHARMACEUTICALS PROVIDES UPDATE ON ONWARD9 PHASE 3 PIVOTAL TRIAL

BRIEF-Adial Pharmaceuticals Announces Modifications To Phase 3 Pivotal Trial Of Ad04 To Protect Subjects From Covid-19

* ADIAL PHARMACEUTICALS INC. - ADIAL PHARMACEUTICALS ANNOUNCES MODIFICATIONS TO PHASE 3 PIVOTAL TRIAL OF AD04 TO PROTECT SUBJECTS FROM COVID-19

BRIEF-Adial Pharmaceuticals Commences Phase 3 Trial Of AD04 For Alcohol Use Disorder

* ADIAL PHARMACEUTICALS INC. - ADIAL PHARMACEUTICALS COMMENCES PHASE 3 TRIAL OF AD04 FOR ALCOHOL USE DISORDER

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up